TY - JOUR
T1 - Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli
AU - Vila, Jordi
AU - Ruiz, Joaquim
AU - Goñi, Pilar
AU - Jimenez De Anta, M. Teresa
PY - 1996/2
Y1 - 1996/2
N2 - The gene parC encodes the A subunit of topoisomerase IV of Escherichia coli. Mutations in the parC region analogous to those in the quinolone resistance-determining region of gyrA were investigated in 27 clinical isolates of E. coli for which ciprofloxacin MICs were 0.007 to 128 μ/ml. Of 15 isolates for which ciprofloxacin MICs were ≥1 μg/ml, 8 showed a change in the serine residue at position 80 (Ser-80), 4 showed a change in Glu-84, and 3 showed changes in both amino acids. No mutations were detected in 12 clinical isolates for which ciprofloxacin MICs were ≤0.25 μg/ml. These findings suggest that Parc from E. coli may be another target for quinolones and that mutations at residues Ser-80 and Glu-84 may contribute to decreased fluoroquinolone susceptibility.
AB - The gene parC encodes the A subunit of topoisomerase IV of Escherichia coli. Mutations in the parC region analogous to those in the quinolone resistance-determining region of gyrA were investigated in 27 clinical isolates of E. coli for which ciprofloxacin MICs were 0.007 to 128 μ/ml. Of 15 isolates for which ciprofloxacin MICs were ≥1 μg/ml, 8 showed a change in the serine residue at position 80 (Ser-80), 4 showed a change in Glu-84, and 3 showed changes in both amino acids. No mutations were detected in 12 clinical isolates for which ciprofloxacin MICs were ≤0.25 μg/ml. These findings suggest that Parc from E. coli may be another target for quinolones and that mutations at residues Ser-80 and Glu-84 may contribute to decreased fluoroquinolone susceptibility.
UR - http://www.scopus.com/inward/record.url?scp=0030033421&partnerID=8YFLogxK
U2 - 10.1128/aac.40.2.491
DO - 10.1128/aac.40.2.491
M3 - Artículo
C2 - 8834907
AN - SCOPUS:0030033421
SN - 0066-4804
VL - 40
SP - 491
EP - 493
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 2
ER -